Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Accured Expenses (2018 - 2025)

Serina Therapeutics (SER) has disclosed Change in Accured Expenses for 8 consecutive years, with $67000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses changed N/A to $67000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$231000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$231000.0 for FY2025, N/A changed from the prior year.
  • Change in Accured Expenses hit $67000.0 in Q4 2025 for Serina Therapeutics, up from -$183000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $403000.0 in Q1 2024 to a low of -$695000.0 in Q4 2021.
  • Historically, Change in Accured Expenses has averaged -$63722.2 across 5 years, with a median of -$26000.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 159.83% in 2022 and later tumbled 3800.0% in 2023.
  • Year by year, Change in Accured Expenses stood at -$695000.0 in 2021, then soared by 99.71% to -$2000.0 in 2022, then crashed by 3800.0% to -$78000.0 in 2023, then skyrocketed by 178.21% to $61000.0 in 2024, then increased by 9.84% to $67000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for SER at $67000.0 in Q4 2025, -$183000.0 in Q3 2025, and $273000.0 in Q2 2025.